BMT/Leukemia

With recent increased understanding of disease genetics and development of new therapies, the treatment of Hematologic Malignancies has revolutionized over the past decade with an explosion of new therapeutic options. Now, patients with diseases such as Acute Leukemia, Myelodysplastic Syndrome, and Multiple Myeloma are living longer and better than ever. 

At the University of Arizona Cancer Center, we personalize therapy according to risk and goals of care using a patient-centered approach. We use novel therapies including immunotherapy, targeted therapy, the latest approved drug combinations, and Hematopoietic Cellular Therapy and Transplant (including autologous, allogenic transplant, and CAR-T cells) to attain the best possible disease outcomes.

We value the importance of treating the patient, the whole patient, and providing compassionate care to our patients.

Featured Clinical Trials

A Phase I/Ib Study of Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide and/or Bendamustine

Phase 1B/II Study of Escalating Doses of Pevonedistat (Tak-924, Formerly MLN4924) Administered in Combination with Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myelogenous Leukemia (AML)

Tucson

Phoenix

Surgical Oncology
Medical Oncology

Staff

Tucson

Clinical Research Coordination

Lora D. Inclan, BA
520-694-9053
Jennifer L Kramer
520-626-6725
Jamison Phelps, BS
520-694-9050

Research Data Coordination

Rosalita Campos
520-626-7446

Regulatory Coordination

Management

Yvonne M. Ruiz